Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Office of National Drug Control Policy
Providers
Officials urge buprenorphine uptake following X-Waiver repeal
Loosened DEA requirements have increased the number of providers who can prescribe buprenorphine for opioid use disorder from 130,000 to 1.8 million.
Dave Muoio
Jan 24, 2023 6:00pm
Vendor data breach impacts HAP, Blue Cross Blue Shield—roundup
Mar 6, 2019 3:05pm
Trump to nominate Jim Carroll as ‘drug czar’
Feb 12, 2018 11:58am
White House sidelines drug policy office in opioid efforts
Feb 7, 2018 11:20am
HHS renews opioid public health emergency status
Jan 22, 2018 11:39am
Trump proposes 95% cut to drug policy office budget
Jan 19, 2018 1:33pm
